NEW YORK—The nonalcoholic beverage category has moved well past Dry January novelty. Cannabis-infused seltzers, dealcoholized wines and zero-proof spirits now sit on shelves at Total Wine, Target, Winn-Dixie and Circle K—four of the largest retail chains in the United States—marking a distribution reach that specialty wellness products rarely achieve this fast.
THC drinks had a breakout year in 2025, graduating from dispensary novelty into a recognized beverage segment that borrowed its marketing language and packaging directly from craft beer and functional-drink brands. The category's retail footprint expansion into mainstream grocery and convenience channels is the clearest sign that consumer demand has crossed a threshold retailers take seriously.
The dealcoholized wine segment presents a harder product problem. Removing alcohol strips aromatic compounds that give wine its complexity, leaving most alternatives thin, sweet and flat—a technical limitation that has kept quality inconsistent across brands. Producers using more advanced dealcoholization methods are differentiating on mouthfeel and flavor retention, and that gap is becoming the primary competitive moat in the category.
Rosé and riesling have emerged as the two white-wine styles most successfully replicated in the NA format, partly because their flavor profiles—fruit-forward, aromatic, moderate tannin—survive the dealcoholization process better than fuller-bodied reds. Red wine remains the hardest category to execute: most NA merlots and cabernets on the market still read as glorified grape juice to consumers who compare them directly against the alcoholic original.
The functional-drink subcategory is fracturing into distinct consumer targets. Relaxation drinks use chamomile, lavender, adaptogens and L-theanine to replicate the wind-down effect of an evening glass of wine. Nootropic drinks target social occasions where consumers want mental clarity instead of impairment. CBD and THC beverages sit in a third lane, using cannabinoids to deliver calm and better sleep—a direct substitute for alcohol's sedative effect without the next-morning consequences.
For equity investors, the category's growth sits almost entirely inside private companies and the beverage divisions of large consumer staples conglomerates. There is no pure-play publicly traded NA beverage stock with meaningful analyst coverage today. The closest proxies are the spirits and beer majors—Constellation Brands, Boston Beer and Molson Coors—all of which have launched or acquired NA lines as defensive plays against volume erosion in their core alcohol businesses.
Boston Beer's Truly and Samuel Adams brands have faced volume pressure for three consecutive years as the hard-seltzer wave that made them institutional favorites reversed. The company has not disclosed what percentage of revenue comes from NA or functional beverages, but management has publicly described the segment as a strategic priority. Boston Beer trades on the New York Stock Exchange under SAM; Molson Coors trades as TAP.
Constellation Brands, which holds the U.S. distribution rights for Corona and Modelo, launched Corona Cero—its zero-alcohol beer—into mainstream U.S. retail in 2024. Modelo Especial remains the top-selling beer in the United States by volume, giving Constellation the retail relationships to place NA extensions without fighting for shelf space. The company reports under STZ on the NYSE.
The cannabis beverage segment carries a separate regulatory layer. THC drinks sold outside licensed dispensaries operate under a legal framework that varies by state and has not been resolved at the federal level. Cronos Group, Tilray Brands and Canopy Growth—the three largest publicly traded cannabis companies—have each flagged beverage as a growth vertical, but none has reported meaningful U.S. revenue from THC drinks given ongoing federal scheduling constraints. Tilray trades as TLRY on Nasdaq; Canopy trades as CGC.
The near-term catalyst to watch is whether any major spirits company—Diageo and Pernod Ricard are the two most likely candidates given their global distribution scale—makes an acquisition in the premium NA or THC beverage space. Diageo has previously invested in cannabis through its stake in Tilray's predecessor and retains the balance sheet to move. An acquisition announcement would be the fastest way to put institutional-grade capital and a public market valuation on a category that currently has neither.
